This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hallegua, D Articles by Klinenberg, J R Search for Related Content PubMed PubMed Citation Articles by Hallegua, D Articles by Klinenberg, J R Social Bookmarking                         What's this?

Cyclosporine for lupus membranous nephritis:experience with ten patients and review of the literature

Department of Rheumatology, Ceders-Sinai Medical Center/UCLA School of Medicine, 8700 Beverly Boulevard, Suite 2003, Los Angeles, CA 90048, USA;David Hallegua, 8737 Beverly Boulevard, Suite 203, Los Angeles, CA 90048, USA

D J Wallace

A L Metzger

R Z Rinaldi

J R Klinenberg

Department of Rheumatology, Ceders-Sinai Medical Center/UCLA School of Medicine, 8700 Beverly Boulevard, Suite 2003, Los Angeles, CA 90048, USA

Objectives: The treatment of lupus membranous nephritis (LMN), a lupus subset that carries a high morbidity, is unsatisfactory. We report our experience in treating LMN with the immunosuppressive drug cyclosporine (CYS).

Methods: We treated 10 patients with systemic lupus erythematosus fulfilling ACR criteria with CYS for at least 12 months and followed renal function, serologic activity and SLEDAI scores. Patient characteristics:8 females, 2 males, 50% Caucasian, mean age 37.3 y (range 22–48), disease duration 108.7 months (range 16–216), nephritis duration 35.5 months (range 12–59), date of biopsy to date of starting treatment 10.7 months (range 0–90). The patients were started on CYS with a mean dose of 3.8 mg/kg (range 2.2–6) and followed for a mean duration of 24.8 months (range 12–59). A Medline search identified all patients with lupus who were given CYS or had LMN in articles from 1966–1999.

Results: Proteinuria improved from a baseline mean of 5588 mg/24 h (range 2712–11 055) to 1404 mg/24 h (range < 150–2652). Serum albumin increased from a baseline mean of 2.8 g=100 ml (range 1.31–3.8) to a mean of 3.9 g/100 ml (range 3–4.5) at last follow-up. There was no significant change in lupus activity as measured by SLEDAI. Nephrotoxicity was common as evidenced by an increase in serum creatinine but it returned to baseline with adjustment of the dose of CYS (20% decrease in the dose of CYS for a 20% increase in serum creatinine). More antihypertensive medications were required to control the blood pressure in these ten patients at the end of the study compared to the onset (total number = 13 versus 6).

Conclusion: Proteinuria and serum albumin improved in all patients on CYS. A literature review is consistent with this. Controlled studies of the use of CYS for membranous lupus nephritis would be useful.

Key Words: cyclosporine (CYS) • lupus membranous nephropathy (LMN) • systemic lupus erythematosus (SLE) • end stage renal disease (ESRD)

Lupus, Vol. 9, No. 4, 241-251 (2000)
DOI: 10.1191/096120300680198935


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. A. Austin III, G. G. Illei, M. J. Braun, and J. E. Balow Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy J. Am. Soc. Nephrol., April 1, 2009; 20(4): 901 - 911. [Abstract] [Full Text] [PDF]

				G. Moroni, A. Doria, and C. Ponticelli Cyclosporine (CsA) in lupus nephritis: assessing the evidence Nephrol. Dial. Transplant., January 1, 2009; 24(1): 15 - 20. [Full Text] [PDF]

				C.-C. Szeto, B. C.-H. Kwan, F. M.-M. Lai, L.-S. Tam, E. K.-M. Li, K.-M. Chow, W. Gang, and P. K.-T. Li Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis Rheumatology, November 1, 2008; 47(11): 1678 - 1681. [Abstract] [Full Text] [PDF]

				K C Tse, M F Lam, S C. Tang, C S. Tang, and T M Chan A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade Lupus, January 1, 2007; 16(1): 46 - 51. [Abstract] [PDF]

				G. Moroni, A. Doria, M. Mosca, O. D. C. Alberighi, G. Ferraccioli, S. Todesco, C. Manno, P. Altieri, R. Ferrara, S. Greco, et al. A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 925 - 932. [Abstract] [Full Text] [PDF]

				V Baca, T Catalan, M Villasis-Keever, G Ramon, A. Morales, and F Rodriguez-Leyva Effect of Low-Dose Cyclosporine A in the Treatment of Refractory Proteinuria in Childhood-Onset Lupus Nephritis Lupus, August 1, 2006; 15(8): 490 - 495. [Abstract] [PDF]

				C. Ponticelli New Therapies for Lupus Nephritis Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 863 - 868. [Full Text] [PDF]

				H A Austin and G G Illei Membranous lupus nephritis Lupus, January 1, 2005; 14(1): 65 - 71. [Abstract] [PDF]

				L-S Tam, E Li, C-C Szeto, S-M Wong, C-B Leung, F Lai, K-C Wong, and S-F Lui Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A Lupus, November 1, 2001; 10(11): 827 - 829. [PDF]